News
Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Media
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conferences
Conference CoverageConference Listing
Publications
More
CME/CE
Continuing Education
Resources
Case-Based Digest Rx Road MapEvents
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Partners
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Gastric Cancers
  • Genitourinary Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head and Neck Cancers
  • Hematology
    • Leukemia
    • Graft-Vs-Host Disease
    • Myeloproliferative Neoplasms
    • Multiple Myeloma
    • Lymphoma
  • Lung Cancer
  • Pediatric Cancer
  • Sarcomas
  • Skin Cancer
    • Melanoma
Advertisement

DANIEL KARLIN, MD

Advertisement

Articles by DANIEL KARLIN, MD

Opioid-Induced Nausea and Vomiting: What the Oncology Nurse Should Know

ByJEANNETTE (JEANNIE) MEYER, MSN, RN, CCRN-K, CCNS, PCCN-K, ACHPN,DANIEL KARLIN, MD,CHRISTOPHER PIETRAS, MD
May 3rd 2019

Up to 40% of patients with cancer who take opioids experience nausea and vomiting.

Advertisement

Latest Updated Articles

  • Opioid-Induced Nausea and Vomiting: What the Oncology Nurse Should Know
    Opioid-Induced Nausea and Vomiting: What the Oncology Nurse Should Know

    Published: May 3rd 2019 | Updated:



Advertisement
Advertisement

Trending on Oncology Nursing News

1

VCN-01 Plus SOC Improves Survival, Is Safe in Metastatic PDAC

2

Buparlisib/Chemo Combo Misses OS Mark in PD-1–Treated Recurrent HNC

3

T-DXd Plus Pertuzumab Sustains PFS Benefit Across HER2+ BC Subgroups

4

Sacituzumab Govitecan/Pembro Maintains QOL, Physical Functioning in mTNBC

5

Older, Male Patients More Likely to Have CIP, Prospective Study Reveals

  • About Us
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Advertise
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us